Patents Examined by Lester L. Lee
  • Patent number: 5280014
    Abstract: The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: January 18, 1994
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Garth J. S. Cooper, Brendan Leighton
  • Patent number: 5278144
    Abstract: Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be conveniently prepared using recombinant techniques.
    Type: Grant
    Filed: September 4, 1990
    Date of Patent: January 11, 1994
    Assignee: Cor Therapeutics, Inc.
    Inventor: David Wolf
  • Patent number: 5278146
    Abstract: Analogs of CRF, which are based upon hCRF, oCRF, sauvagine and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, .beta.-endorphin, .beta.-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels and/or an increase in blood pressure over an extended period of time. One CRF agonist which has been found to be particularly potent is: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Va l-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-L eu-Leu-Asp-Ile-Ala-NH.sub.2. In these agonist analogs, one or more of the first six N-terminal residues may be deleted and/or the N-terminal alpha-amino group may be acylated by an acylating agent containing up to 7 carbon atoms. A number of other substitutions may also be made throughout the chain.
    Type: Grant
    Filed: June 29, 1992
    Date of Patent: January 11, 1994
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr.
  • Patent number: 5273960
    Abstract: The present invention relates to a process for the preparation of high purity crystalline peptides Arg Lys Asp hydrate acetate and Arg Lys Asp Val from crude, amorphous peptides Arg Lys Asp and Arg Lys Asp Val hydrate acetate.The process is characterized in thatthe crude, amorphous peptide Arg Lys Asp or Arg Lys Asp Val is let stand at room temperature in 5 to 20 unit volume of ethanol containing 0.5 to 4.0% by volume of acetic acid and 5 to 25% by volume of water, wherein the volume unit is calculated for the mass unit of the material and mass unit relates to volume unit as g relates to ml,then the crystallized peptide is separated from the crystalline suspension, preferably after cooling.
    Type: Grant
    Filed: August 23, 1991
    Date of Patent: December 28, 1993
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Olga Nyeki, Istvan Schon, Laszlo Denes, Gyorgy Hajos, Laszlo Szporny, Geza Ivanyi, Tamas berhardt, Lajos Kovacs, Imre Peter, Maria Gazdag, Zsuzsanna Muck, Iidiko berhardt, Gizella Lorant
  • Patent number: 5274075
    Abstract: The invention includes human .epsilon. chain transmembrane anchor peptide resulting from mRNA splicing other than the C.epsilon.4 exon, the .epsilon.m1 exon, and the .epsilon.m2 exon. Two new peptides in particular have been specifically identified. These novel peptides are not present in the conventional secreted (and circulating) IgE. These peptides provide antigenic sites for antibody binding. Thus, the invention further includes antibodies to such peptide segments, as well as such antibodies conjugated to cytotoxic agents, and their use in extracorporeal or in vivo therapy.
    Type: Grant
    Filed: April 27, 1990
    Date of Patent: December 28, 1993
    Assignee: Tanox Biosystems, Inc.
    Inventor: Tse W. Chang
  • Patent number: 5272252
    Abstract: Synthetic pulmonary surfactants having antioxidant properties consisting of a complex of a polypeptide, with an antioxidant moiety, having an alpha-helical structure and a lipid consisting of one or more of the lipids associated with natural pulmonary surfactant were prepared. These surfactants are useful in the treatment of respiratory distress syndrome.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: December 21, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Larry R. McLean, Marquerite H. Payne
  • Patent number: 5270302
    Abstract: Selective and potent Type-A CCK receptor agonists of formula (I):X--Y--Z--Q (I)or a pharmaceutically acceptable salt thereof, wherein,X is selected from ##STR1## Y is selected from ##STR2## Z is ##STR3## and Q is ##STR4## or pharmaceutically-acceptable salts thereof, useful in the treatment of gastrointestinal disorders (including gallbladder disorders), central nervous system disorders, insulin-related disorders and pain, as well as in appetite regulation.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: December 14, 1993
    Assignee: Abbott Laboratories
    Inventors: Kazumi Shiosaki, Alex M. Nadzan, Hana Kopecka, Youe-Kong Shue, Mark W. Holladay, Chun W. Lin, Hugh N. Nellans
  • Patent number: 5266561
    Abstract: Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.
    Type: Grant
    Filed: June 4, 1991
    Date of Patent: November 30, 1993
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Garth J. S. Cooper, Howard Greene, Jr.
  • Patent number: 5264419
    Abstract: Novel peptoids of .alpha.-substituted Trp derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, or opioids. The compounds are also useful in the treatment and/or prevention of panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the peptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: November 23, 1993
    Assignee: Warner-Lambert Company
    Inventors: David C. Horwell, Martyn C. Pritchard, Edward Roberts
  • Patent number: 5264213
    Abstract: A highly active water-dispersible pesticide formulation is prepared by dissolving at least a part of a benzoyl phenyl urea series insecticidal compound in an organic solvent, contacting the so obtained mixture with a carrier material, and pulverizing the resulting mixture. The pesticidal formulation obtained has higher pesticidal activity than formulations prepared by a conventional dry methods.
    Type: Grant
    Filed: July 7, 1989
    Date of Patent: November 23, 1993
    Assignee: DowElanco
    Inventors: Tetsuya Shibahara, Naohiko Kondo, Jun Kato
  • Patent number: 5262519
    Abstract: The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans and also resist enzymatic degradation in the body. Certain preferred peptides have the formula:(B)R.sub.1 -Ala-Asp-Ala-Ile-Phe-Thr-R.sub.8 -Ser-Tyr-Arg-Lys-Val-Leu-R.sub.15 -R.sub.16 - Leu-Ser-Ala-Arg-Lys-Leu-Leu-R.sub.24 -R.sub.25 -Ile-Nle-R.sub.28 -Arg-Y wherein R.sub.1 is Tyr, D-Tyr, Phe, D-Phe, His or D-His; B is H or N.sup..alpha. Me; R.sub.8 is Ala, Aib or Asn; R.sub.15 is Gly or Ala; R.sub.16 is Ala, Aib or Gln; R.sub.24 is Ala, Aib or Gln; R.sub.25 is Ala, Aib or Asp; R.sub.28 is Ser or Asn; Y is NHR with R being H or lower alkyl; provided that at least one of R.sub.8, R.sub.16, R.sub.24 and R.sub.25 is Ala or Aib.
    Type: Grant
    Filed: May 15, 1991
    Date of Patent: November 16, 1993
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr.
  • Patent number: 5260277
    Abstract: Guanidinyl-containing compounds, and related compounds and salts, useful as cell receptor antagonists for modulating cell adhesion via integrin receptors and/or fibronectin receptors, are disclosed. Methods for synthesizing, testing, formulating, and using the compounds as therapeutic agents are also disclosed.
    Type: Grant
    Filed: September 10, 1990
    Date of Patent: November 9, 1993
    Assignee: Tanabe Seiyaku Co., Ltd.
    Inventor: Thomas C. McKenzie
  • Patent number: 5260416
    Abstract: Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane are disclosed. For IgE, the epitopes are present on IgE-bearing B cells but not basophils or the secreted, soluble form of IgE. The epitope can be exploited for therapy and diagnosis. For example, antibodies or immunotoxins specific for the epitopes associated with the anchor domain of IgE can be used to selectively destroy IgE-bearing lymphocytes, thus blocking IgE-mediated allergic reactions.
    Type: Grant
    Filed: January 23, 1990
    Date of Patent: November 9, 1993
    Assignee: Tanox Biosystems, Inc.
    Inventor: Tse-wen Chang
  • Patent number: 5260273
    Abstract: A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula (Z.sub.a U.sub.b).sub.c Z.sub.d, wherein:Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;U is a hydrophobic amino acid residue independently selected from the group consisting of V, I, L, C, Y and F;a has an average value of about 1 to about 5;b has an average value of about 3 to about 20;c is 1 to 10; andd is 1 to 3;said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
    Type: Grant
    Filed: June 14, 1991
    Date of Patent: November 9, 1993
    Assignee: The Scripps Research Institute
    Inventors: Charles G. Cochrane, Susan D. Revak
  • Patent number: 5260274
    Abstract: Peptides which inhibit the binding of von Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.
    Type: Grant
    Filed: July 3, 1991
    Date of Patent: November 9, 1993
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Theodore S. Zimmerman, Paul A. Foster, Carol A. Fulcher
  • Patent number: 5260276
    Abstract: Novel linear and monocyclic antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling hypertension, myocardial infarction, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute renal failure, preeclampsia, and diabetes.
    Type: Grant
    Filed: June 14, 1991
    Date of Patent: November 9, 1993
    Assignee: Warner-Lambert Company
    Inventors: Wayne L. Cody, Annette M. Doherty, John X. He
  • Patent number: 5260272
    Abstract: Polypeptides of the formulapoly (X).sub.m (Y).sub.n,whereinX is selected from the group consisting of aspartate, glutamate, glutamine, asparagine, mixtures and block polymers thereof,Y is selected from the group consisting of phosphoserine, sulfoserine, phosphohomoserine, phosphotyrosine, phosphothreonine, phosphoglutamine, phosphoasparagine, serine, alanine, dehydroalanine and mixtures thereof,m=5-199 andn=1-10have been demonstrated to inhibit mineral deposition, and can be employed in the inhibition of mineral deposition in both in vitro and in vivo applications. Serine-containing polypeptides can be thermally synthesized by combining the necessary amino acid residues in a reaction vessel, eliminating oxygen to preclude charring, and heating said reaction vessel in a heating medium to a temperature of about 155.degree. C.
    Type: Grant
    Filed: March 29, 1991
    Date of Patent: November 9, 1993
    Assignee: University of South Alabama
    Inventors: Julie Donachy, Steven Sikes
  • Patent number: 5258368
    Abstract: Methods, compounds and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator peptides to said host. Also provided are methods for producing such peptide compounds.
    Type: Grant
    Filed: April 28, 1992
    Date of Patent: November 2, 1993
    Assignee: Scios Nova, Inc.
    Inventors: John A. Lewicki, Robert M. Scarborough, Jr.
  • Patent number: 5258420
    Abstract: A bone cement is disclosed wherein the liquid component contains a therapeutic or diagnostic substance in combination with an emulsifying agent for said substance.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: November 2, 1993
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Jessica Posey-Dowty, Paul A. Higham, Nestor A. Arroyo, Casper F. Stark
  • Patent number: 5254534
    Abstract: An adjuvant for cancer immunotherapy with an immuno-activating agent, which comprises a colony stimulating factor as an active ingredient, can remarkably increase the antitumor effect of said immunoactivating agent.
    Type: Grant
    Filed: January 30, 1989
    Date of Patent: October 19, 1993
    Assignees: Green Cross Corporation, Milk Industry Co.
    Inventors: Masaaki Tachibana, Hiroshi Tazaki